Cystatin B increases autophagic flux by sustaining proteolytic activity of cathepsin B and fuels glycolysis in pancreatic cancer: CSTB orchestrates autophagy and glycolysis in PDAC

Abstract Background Both autophagy and glycolysis are essential for pancreatic ductal adenocarcinoma (PDAC) survival due to desmoplasia. We investigated whether targeting a hub gene which participates in both processes could be an efficient strategy for PDAC treatment. Methods The expression pattern of glycolysis signatures (GS) and autophagy signatures (AS) and their correlation with cystatin B (CSTB) in PDAC were analysed. It was discovered how CSTB affected the growth, glycolysis, and autophagy of PDAC cells. We assessed competitive binding to cathepsin B (CTSB) between CSTB and cystatin C (CSTC) via immunoprecipitation (IP) and immunofluorescence (IF). Chromatin immunoprecipitation quantitative polymerase chain reaction (ChIP‐qPCR) and luciferase reporter gene assays were used to unveil the mechanism underlying CSTB upregulation. The expression pattern of CSTB was examined in clinical samples and KrasG12D/+, Trp53R172H/+, Pdx1‐Cre (KPC) mice. Results GS and AS were enriched and closely associated in PDAC tissues. CSTB increased autophagic flux and provided substrates for glycolysis. CSTB knockdown attenuated the proliferation of PDAC cells and patient‐derived xenografts. The liquid chromatography‐tandem mass spectrometry assay indicated CSTB interacted with CTSB and contributed to the proteolytic activity of CTSB in lysosomes. IF and IP assays demonstrated that CSTB competed with CSTC to bind to CTSB. Mutation of the key sites of CSTB abolished the interaction between CSTB and CTSB. CSTB was highly expressed in PDAC due to H3K27acetylation and SP1 expression. High expression of CSTB in PDAC was observed in tissue microarray and patients’ serum samples. Conclusions Our work demonstrated the tumorigenic roles of autophagy and glycolysis in PDAC. CSTB is a key role in orchestrating these processes to ensure energy supply of PDAC cells.

[1]  Shiyong Wu,et al.  Prognosis and Characterization of Immune Microenvironment in Acute Myeloid Leukemia Through Identification of an Autophagy-Related Signature , 2021, Frontiers in Immunology.

[2]  Jun Zeng,et al.  A Correlation Study of Prognostic Risk Prediction for Colorectal Cancer Based on Autophagy Signature Genes , 2021, Frontiers in Oncology.

[3]  R. Cao,et al.  Identification of autophagy‐related genes signature predicts chemotherapeutic and immunotherapeutic efficiency in bladder cancer (BLCA) , 2021, Journal of cellular and molecular medicine.

[4]  Lianfang Zheng,et al.  Targeting hypoxic tumor microenvironment in pancreatic cancer , 2021, Journal of Hematology & Oncology.

[5]  Shanlong Huang,et al.  The effect of a novel glycolysis-related gene signature on progression, prognosis and immune microenvironment of renal cell carcinoma , 2020, BMC Cancer.

[6]  Fan Lin,et al.  Identification and validation of a six-gene signature associated with glycolysis to predict the prognosis of patients with cervical cancer , 2020, BMC Cancer.

[7]  Jiazhe Lin,et al.  A risk signature of three autophagy-related genes for predicting lower grade glioma survival is associated with tumor immune microenvironment. , 2020, Genomics.

[8]  P. Lu,et al.  Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma , 2020, Cancer Research.

[9]  Lan Zhao,et al.  Glycolysis gene expression profilings screen for prognostic risk signature of hepatocellular carcinoma , 2019, Aging.

[10]  M. Reginato,et al.  Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer , 2019, BMC Biology.

[11]  Yijuan Zhang,et al.  Macropinocytosis in Cancer: A Complex Signaling Network. , 2019, Trends in cancer.

[12]  G. Mills,et al.  Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy , 2019, Nature Metabolism.

[13]  E. Petricoin,et al.  Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer , 2019, Nature Medicine.

[14]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[15]  J. Rathmell,et al.  Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release , 2018, Nature.

[16]  G. Xiao,et al.  Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis , 2018, Clinical Cancer Research.

[17]  Torsten Schwede,et al.  SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..

[18]  Y. Zeng,et al.  Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of HK2 (hexokinase 2) , 2018, Autophagy.

[19]  The Uniprot Consortium.  UniProt: the universal protein knowledgebase , 2018, Nucleic acids research.

[20]  Neil D. Rawlings,et al.  The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database , 2017, Nucleic Acids Res..

[21]  J. Kos,et al.  Cysteine cathepsins B and X promote epithelial-mesenchymal transition of tumor cells. , 2017, European journal of cell biology.

[22]  A. Thorburn,et al.  Targeting autophagy in cancer , 2017, Nature Reviews Cancer.

[23]  Jun Li,et al.  Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice. , 2017, Gastroenterology.

[24]  H. Motaln,et al.  Proteases and cytokines as mediators of interactions between cancer and stromal cells in tumours , 2017, Biological chemistry.

[25]  E. White,et al.  Autophagy and Tumor Metabolism. , 2017, Cell metabolism.

[26]  Jinxing Huang,et al.  CSTB Downregulation Promotes Cell Proliferation and Migration and Suppresses Apoptosis in Gastric Cancer SGC-7901 Cell Line. , 2016, Oncology research.

[27]  Li-Yan Xu,et al.  Tissue Levels of Stefin A and Stefin B in Hepatocellular Carcinoma , 2016, Anatomical record.

[28]  N. Bardeesy,et al.  Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up. , 2015, Cancer discovery.

[29]  J. Joyce,et al.  Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response , 2015, Nature Reviews Cancer.

[30]  K. Ross,et al.  Transcriptional control of autophagy–lysosome function drives pancreatic cancer metabolism , 2015, Nature.

[31]  R. Wada,et al.  Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma. , 2015, International journal of oncology.

[32]  N. Hay,et al.  The pentose phosphate pathway and cancer. , 2014, Trends in biochemical sciences.

[33]  O. Vasiljeva,et al.  Stefin B deficiency reduces tumor growth via sensitization of tumor cells to oxidative stress in a breast cancer model , 2014, Oncogene.

[34]  Zhiping Weng,et al.  ZDOCK server: interactive docking prediction of protein-protein complexes and symmetric multimers , 2014, Bioinform..

[35]  Myung-Shik Lee,et al.  Autophagy—a key player in cellular and body metabolism , 2014, Nature Reviews Endocrinology.

[36]  Amy Y. M. Au,et al.  p53 status determines the role of autophagy in pancreatic tumour development , 2013, Nature.

[37]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[38]  R. Bjerkvig,et al.  The regulation of cysteine cathepsins and cystatins in human gliomas , 2012, International journal of cancer.

[39]  D. Sabatini,et al.  Cancer cell metabolism: one hallmark, many faces. , 2012, Cancer discovery.

[40]  Masaaki Komatsu,et al.  Autophagy: Renovation of Cells and Tissues , 2011, Cell.

[41]  Zhiping Weng,et al.  Accelerating Protein Docking in ZDOCK Using an Advanced 3D Convolution Library , 2011, PloS one.

[42]  Marc Liesa,et al.  Pancreatic cancers require autophagy for tumor growth. , 2011, Genes & development.

[43]  M. K. Kim,et al.  Development of a fluorescent microsphere immunoassay for cystatin B (CSTB) in serum of patients with hepatocellular carcinoma , 2011, Clinical chemistry and laboratory medicine.

[44]  D. Turk,et al.  Cystatins: biochemical and structural properties, and medical relevance. , 2008, Frontiers in bioscience : a journal and virtual library.

[45]  Dae‐Ghon Kim,et al.  Identification of Cystatin B as a Potential Serum Marker in Hepatocellular Carcinoma , 2008, Clinical Cancer Research.

[46]  D. Hanahan,et al.  Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. , 2006, Genes & development.

[47]  A. Krüger,et al.  Reduction of experimental human fibrosarcoma lung metastasis in mice by adenovirus-mediated cystatin C overexpression in the host. , 2005, Cancer research.

[48]  A. Alavi,et al.  Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.

[49]  Cathy H. Wu,et al.  UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..

[50]  G. Kouraklis,et al.  Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells , 2002, Oncogene.

[51]  P. Strojan,et al.  Cathepsin B and L and stefin A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck. , 2001, Neoplasma.

[52]  I J Christensen,et al.  Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  J. Kos,et al.  Clinical and Experimental Studies of Cysteine Cathepsins and Their Inhibitors in Human Brain Tumors , 2000, The International journal of biological markers.

[54]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[55]  J. Kos,et al.  Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). , 1998, Oncology reports.

[56]  J. Thornton,et al.  AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR , 1996, Journal of biomolecular NMR.

[57]  B. Lenarčič,et al.  Differences in specificity for the interactions of stefins A, B and D with cysteine proteinases , 1996, FEBS letters.

[58]  Robert Huber,et al.  The refined 2.15 A X‐ray crystal structure of human liver cathepsin B: the structural basis for its specificity. , 1991, The EMBO journal.

[59]  R. Huber,et al.  The refined 2.4 A X‐ray crystal structure of recombinant human stefin B in complex with the cysteine proteinase papain: a novel type of proteinase inhibitor interaction. , 1990, The EMBO journal.

[60]  W. Bode,et al.  The 2.0 A X‐ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. , 1988, The EMBO journal.

[61]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[62]  S. Weinhouse.  On respiratory impairment in cancer cells. , 1956, Science.

[63]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.